coronaviru
main
proteas
pro
consid
major
target
drug
suitabl
combat
coronaviru
infect
includ
sever
acut
respiratori
syndrom
sar
studi
comprehens
hplcand
fretsubstratebas
screen
variou
electrophil
compound
perform
identifi
potenti
pro
inhibitor
data
reveal
coronavir
main
proteas
inhibit
aziridineand
among
transconfigur
glyglycontain
peptid
found
potent
inhibitor
coronavirus
import
pathogen
mainli
caus
respiratori
enter
diseas
human
livestock
domest
anim
previous
unknown
coronaviru
call
sarscov
identifi
caus
agent
sever
acut
respiratori
syndrom
sar
newli
emerg
diseas
within
week
spread
like
origin
guangdong
provinc
china
neighbor
region
mani
countri
coronavirus
plusstrand
rna
virus
use
complex
enzymolog
replic
largest
rna
genom
current
known
synthes
extens
set
leadercontain
subgenom
mrna
encod
viral
structur
protein
sever
speciesspecif
protein
unknown
function
enzymat
activ
requir
viral
rna
synthesi
part
two
virusencod
polyprotein
kda
respect
extens
process
two
three
viral
proteas
yield
matur
protein
multipl
process
intermedi
cleavag
mediat
coronaviru
main
proteas
pro
cystein
proteas
featur
twobbarrel
structur
domain
ii
link
ctermin
ahel
domain
iii
structur
domain
ii
similar
chymotrypsinlik
serin
proteas
essenti
role
proteolyt
process
pro
consid
attract
target
antivir
drug
sar
coronaviru
infect
number
potenti
inhibitor
propos
employ
molecular
model
virtual
screen
techniqu
howev
inhibitori
potenc
compound
yet
verifi
small
number
potent
proteas
inhibitor
identifi
screen
assay
thu
far
studi
use
commerci
avail
compound
librari
screen
assay
except
peptidyl
chloromethylketon
recent
publish
etacryn
acid
deriv
none
potent
compound
identifi
date
develop
predict
target
activ
site
cystein
residu
lack
activesit
direct
lead
structur
motiv
search
new
lead
proven
activesit
direct
activ
scrutin
compound
contain
electrophil
build
block
aziridin
epoxid
see
tabl
known
react
nucleophil
amino
acid
within
activ
site
proteas
exampl
transconfigur
epoxysuccinylbas
peptideslik
ci
ci
r
structur
see
ni
amino
acid
abbrevi
threelett
code
ni
inhibit
tmr
threememb
ring
percentag
inhibit
obtain
fretbas
assay
valu
mean
valu
least
independ
assay
b
percentag
inhibit
obtain
hplc
assay
mean
valu
four
independ
assay
c
ratio
diastereom
respect
aziridin
highli
activ
inhibitor
cystein
proteas
propos
inhibit
mechan
alkyl
activ
site
cystein
residu
howev
report
inact
coronavir
main
proteas
picornavir
proteas
cisconfigur
epoxid
hand
known
inhibit
aspart
proteas
alkyl
one
aspart
residu
within
activ
site
bepoxi
keton
report
inhibit
serin
cystein
proteas
depend
stereochemistri
epoxid
ring
investig
whether
epoxid
aziridin
could
serv
electrophil
build
block
coronavir
main
proteas
evalu
stereochemistri
prefer
proteas
transand
cisconfigur
differ
substitut
threememb
heterocycl
includ
screen
first
screen
perform
hplcbase
assay
use
vsvnstlqsglrkma
substrat
fig
second
screen
extend
use
less
timeconsum
less
intric
fluorimetr
assay
use
fretpair
label
substrat
tabl
screen
reveal
transconfigur
nunsubstitut
eto
aziglyglyobn
show
inhibit
sarscov
pro
hplc
assay
fig
inhibit
fluorimetr
assay
lm
show
inhibit
potent
compound
tabl
within
seri
transconfigur
aziridin
gli
deriv
show
consider
activ
weak
activ
found
derivativescontain
larger
amino
acid
contrast
good
inhibitor
proteas
eg
inhibit
cathepsin
l
k
lm
studi
also
reveal
epoxid
aziridin
build
block
alon
bear
amino
acid
moieti
activ
within
seri
cisconfigur
epoxid
aziridin
weak
inhibit
exhibit
nbenzyl
aziridin
pheobncontain
epoxid
free
acid
inact
diastereomer
mixtur
pheobncontain
nbenzyl
aziridin
slightli
activ
pure
compound
suggest
diastereom
r
r
configur
aziridin
ring
potent
isom
except
activ
rang
wherea
inact
interestingli
epoxid
compound
without
electronwithdraw
substitu
threememb
ring
show
activ
result
show
contrast
proteas
inhibit
transconfigur
threememb
heterocycl
cisconfigur
analogu
serv
build
block
inhibitor
proteas
well
better
understand
relev
interact
potent
inhibitor
sarscov
pro
dock
experi
use
flexx
carri
bind
site
extract
recent
publish
structur
complex
sarscov
pro
peptpeptidyl
chloromethyl
keton
cmk
pdb
code
figur
show
dock
overlay
cmk
green
aziridinyl
peptid
orang
propos
bind
mode
substrat
analogu
hexapeptidyl
chloromethyl
keton
inhibitor
cbzvalasnserthrleuglncmk
shown
found
elimin
coval
bond
subsequ
minim
activ
site
sarscov
pro
dock
aziridin
deriv
orang
suggest
reactiv
center
compound
locat
close
proxim
sulfur
cocrystal
ligand
main
part
locat
pocket
enzym
compound
interact
enzym
describ
hydrogen
bond
amino
acid
bchain
achain
fig
suggest
better
fit
protein
dimer
form
solut
high
concentr
suppos
activ
enzym
form
dock
conform
hydrophob
interact
found
termin
ethyl
group
group
posit
proxim
pocket
dock
conform
termin
benzyl
residu
solvent
expos
suggest
group
overli
import
high
biolog
activ
sinc
neither
ethyl
benzyl
group
show
optim
fit
enzym
number
possibl
synthet
optim
conceiv
includ
enlarg
ethyl
group
replac
benzyl
group
amid
group
mimick
side
chain
gln
suppos
optim
residu
pocket
context
modif
peptid
natur
peptidomimet
one
also
kept
mind
due
pharmacokinet
reason
summari
comprehens
screen
electrophil
compound
reveal
transconfigur
modest
activesit
direct
sarscov
pro
inhibitor
potenti
optim
addit
aziridineand
acidcontain
compound
also
show
weak
inhibitori
activ
activ
might
enhanc
electrophil
build
block
link
appropri
amino
acid
eg
gln
substrat
analogu
peptid
peptidomimet
